Tianda Pharmaceuticals Limited provided group earnings guidance for the nine months period from April 1, 2022 to December 31, 2022. As stated in the announcement of the company dated 25 November 2022, the financial year end date of the company has been changed from 31 March to 31 December. In light of this change, the audited consolidated financial statements for the current period cover the nine-month period from 1 April 2022 to 31 December 2022 and the audited comparative figures cover the twelve-month period from 1 April 2021 to 31 March 2022.

The board of directors of the company informed the shareholders of the company and potential investors that based on the preliminary assessments on the Group's unaudited consolidated management accounts for the Current Financial Period, the Group is expected to record a loss attributable to owners of the parent for the Current Financial Period ranging from HKD 39.0 million to HKD 43.0 million, as compared to the loss of HKD 19.8 million in the Previous Financial Year. Excluding R&D expenses and certain one-off gains and losses, the adjusted loss attributable to owners of the parent is expected to be reduced from HKD 23.0 million in the Previous Financial Year to ranging from HKD 2.5 million to HKD 6.5 million in the Current Financial Period.